Skip to main content

Venture Capital Firm  I  Home

Innovation.
Clarity.
Execution.

A Venture Capital Firm for Visionary Innovators.

Advent Life Sciences is one of the leading trans-Atlantic venture investors focused on building innovative Life Sciences businesses in the UK, Europe and the USA.

We are a highly experienced team with a long-standing track record of entrepreneurial and investment success. We do this by turning break-through science into approved medicines or medical products.

We start and invest in early and mid-stage companies with a first-in-class or best-in-class approach.
Our investments are focused on new drug discovery across all modalities, med tech, enabling technologies and vaccines.
About

As entrepreneurs and experienced, pragmatic investors, we bring the intellectual capital of our well-connected team to support each investment.

We take a hands-on approach and work in close alignment and partnership with our management teams to realise their vision with the goal of achieving superior financial returns by bringing innovation to patients.
Team

Innovation.

We are backing exceptional innovation early.

Since the year 2006, Advent-backed companies have brought fifteen innovative medicines and products to approval with our initial investment often being as early as Seed stage or Series A.

As the mid- and late-stage clinical pipelines of our portfolio companies continue to grow, this number looks set to increase each year.

Portfolio

Latest Press Releases

26 September 2023 in Amphista Therapeutics, Press Release, Private Companies

Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb

Press Release.   PRESS RELEASE   Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb   Cambridge, UK, September 26th, 2023 – Amphista Therapeutics (“the Company”…
Read More
9 August 2023 in Aleta Biotherapeutics, Press Release, Private Companies

Aleta Biotherapeutics Granted MHRA Clinical Trial Authorization for Biologic CAR T-Cell Engager ALETA-001

Press Release.   Aleta Biotherapeutics Granted MHRA Clinical Trial Authorization for Biologic CAR T-Cell Engager ALETA-001   Aleta’s lead program, ALETA-001 has clinical support from collaborator Cancer Research UK, which…
Read More
2 June 2023 in Artax Biopharma, Press Release, Private Companies

Artax Biopharma Announces Positive Phase 1 Results for AX-158, Company’s First-in-Class Oral Immunomodulator Developed to Treat T Cell-Mediated Diseases

Press Release.   Artax Biopharma Announces Positive Phase 1 Results for AX-158, Company’s First-in-Class Oral Immunomodulator Developed to Treat T Cell-Mediated Diseases   Phase 1 Findings Demonstrated that Investigational Agent…
Read More

About

Leading Venture Investors
Learn More

Portfolio

Innovative Life Sciences Companies
Learn More